Table 3.
Treatment effects on self-efficacy from mixed linear models
| 6 months Mean (95% CI) |
18 months Mean (95% CI) |
Change at 18 months (95% CI) |
18 Months | ||
|---|---|---|---|---|---|
| p value | Effect size | ||||
| Balance efficacy | |||||
| E | 83.76 (81.58 to 85.94) | 80.90 (78.77 to 83.03) | 1.89 (−0.24 to 4.02) | .0019 | – |
| D | 83.26 (81.08 to 85.44) | 80.82 (78.69 to 82.95) | 1.81 (−0.32 to 3.94) | −0.00 | |
| D+E | 85.39 (83.30 to 87.48) | 85.44 (83.32 to 87.56) | 6.43 (4.31 to 8.55) | 0.25 | |
| Duration efficacy | |||||
| E | 69.03 (64.81 to 73.24) | 65.97 (61.81 to 70.12) | 13.56 (9.40 to 17.72) | <0.0001 | – |
| D | 59.30 (55.07 to 63.54) | 59.69 (55.51 to 63.87) | 7.29 (3.10 to 11.47) | −0.22 | |
| D+E | 74.59 (70.50 to 78.68) | 74.10 (69.99 to 78.22) | 21.70 (17.59 to 25.81) | 0.28 | |
| Gait efficacy | |||||
| E | 82.17 (79.47 to 84.88) | 81.18 (78.51 to 83.84) | 3.12 (0.46 to 5.79) | 0.0039 | – |
| D | 82.26 (79.50 to 85.02) | 81.01 (78.32 to 83.71) | 2.96 (0.27 to 5.65) | −0.01 | |
| D+E | 86.46 (83.84 to 89.09) | 86.49 (83.83 to 89.14) | 8.43 (5.78 to 11.09) | 0.24 | |
All 6- and 18-month means are adjusted for baseline values, baseline body mass index, and gender.